We help you find the best answers when you need them most.
There are an increasing number of low prevalence genetic alterations with matched FDA-approved therapies, while at the same time requiring smaller biopsy sizes for testing. Comprehensive molecular testing upfront rather than serial testing is the best approach to conserve precious patient tissue and maximize the chance of identifying an important biomarker that informs treatment decisions. Our evidence team consists of physicians and doctoral level scientists who stay current on literature identifying high-level evidence of biomarker-therapy associations, and condense this information into an easy to read molecular report.
Precision Medicine and Cancer Care
Given the explosion of scientific progress on matching the best therapy to the appropriate patient at the right time, it is crucial to receive all of the biomarker and tumor signature information in a single test with a fast turnaround time.
While this was limited to simple mutations in the past, we are now seeing the rapid development of more complex biomarkers, such as gene fusion events or molecular signatures. In addition, biomarkers with matched therapies are relevant in a pan-cancer fashion, such as NTRK and NRG1 gene fusions or MSIH-H status. This complexity can only be addressed by performing comprehensive molecular profiling with in-depth analysis of DNA, RNA and proteins.
Caris Molecular Intelligence enables clinicians to:
Caris has one of the largest and most comprehensive databases of combined molecular and clinical outcomes data in the world, and we are actively employing advanced machine learning capabilities with the database to identify unique molecular signatures.
Our AI-powered tools utilize Caris Molecular Intelligence® tumor profiling results to inform decision making, analyzing historical clinical and outcome data to learn from the past and provide a better future for treatments outcomes. We have launched two AI clinical testing applications that currently available:
Using a cutting-edge artificial intelligence (AI) platform, we identified a molecular signature that is highly predictive of benefit from first-line chemotherapy with FOLFOX (in combination with bevacizumab) in patients with metastatic colorectal cancer. This signature was validated in 2 independent datasets, which included patients from the recently published TRIBE2 study. This signature, called FOLFOXai, is the first commercially available AI signature for the prediction of benefit from standard chemotherapy.
We have used machine learning to develop a highly accurate molecular disease classifier to assist with diagnosis based on DNA and RNA sequencing data. This predictor can be ordered by the oncologist to assist in any case where the diagnosis is uncertain.
The Caris Molecular Tumor Board provides the opportunity to interact with cancer experts from across the country to review molecular information on specific patient cases of a requesting oncologist. This utilizes an on-demand platform that is an innovative, real-time approach to deciphering complex data and treatment decisions on difficult-to-interpret cases. The Caris Molecular Tumor Board allows oncologists to focus their efforts on what matters most – developing the most informed and personalized treatment strategies for their patients.
Our platform facilitates asynchronous discussions to collaborate more efficiently on patient cases while providing:
We're pushing the boundaries of precision medicine
Connecting patients with the most up-to-date and relevant clinical trials
Caris helps patients access the best possible treatment